Tags : ADC Therapeutics

Freenome Signs an Agreement with ADC Therapeutics to Develop Biomarker

Shots: ADC Therapeutics’s to utilize Freenome’s multiomics platform to identify biomarkers correlating with clinical response to ADC’s ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) The focus of the collaboration is to develop innovative cancer therapies, highlighting the potential of Freenome’s platform providing tumor and immune signatures for hematological […]Read More

ADC Therapeutics and Sophia Genetics Collaborate to Identify Biomarkers in

Shots: The companies enter into a collaboration to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine). ADC Therapeutics is currently assessing ADCT-402 in P-II study in patients with r/r DLBCL Sophia Genetic will analyze cell-free DNA (cfDNA) samples extracted from blood patients participating in ADC Therapeutics’ Phase II study utilizing Sophia’s technology, […]Read More

ADC Therapeutics Signs a License Agreement with Adagene for its

Shots: Adagene to receive upfront, development & commercial milestones, research funding and royalties on sales with certain commercialization rights for Greater China.  ADC Therapeutics to utilize Adagene’s SAFEbody technology generating Abs that will further combine with its pyrrolobenzodiazepine (PBD) cytotoxic payload technology to develop masked ADCs for solid tumors ADC Therapeutics also has an option […]Read More